Skip to main content

Table 2 Clinical data profile of pre- and post-pitavastatin treatment

From: Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association

Variables

n

baseline

n

Post-treatment

Change (%)

P value

Body weight (kg)

53

64.1 ± 15.4

52

64.4 ± 16.2

0.7 ± 2.4

0.052

HbAlc (%)

53

7.1 ± 0.80

53

7.2 ± 0.84

1.6 ± 7.6

0.13

eGFR (ml/min/m2)

52

75.4 ± 16.9

51

76.8 ± 16.5

4.2 ± 17.2

0.18

BUN (mg/dL)

52

14.7 ± 4.2

50

14.8 ± 3.9

−2.3 ± 23.8

0.49

Uric acid (mg/dL)

52

5.2 ± 1.4

51

4.9 ± 1.2

−4.7 ± 14.1

0.02

TC (mg/dL)

53

234.3 ± 28.9

48

173.0 ± 25.8

−25.7 ± 9.9

<0.01

TG (mg/dL)

53

146.7 ± 74.1

48

134.2 ± 87.0

−4.1 ± 55.3

0.61

HDL-C (mg/dL)

53

58.8 ± 14.8

49

58.7 ± 15.5

−0.6 ± 11.4

0.7

LDL-C (mg/dL)

53

152.1 ± 29.2

49

91.2 ± 25.4

−39.4 ± 13.6

<0.01

sd LDL-C (mg/dL)

53

52.0 ± 18.1

49

28.7 ± 10.4

−41.7 ± 18.0

<0.01

sd LDL-C/LDL-C (%)

53

33.9 ± 8.4

49

31.6 ± 7.3

−4.5 ± 15.6

0.047

ApoA-I (mg/dL)

53

142.9 ± 26.6

48

148.5 ± 26.7

3.5 ± 8.4

<0.01

CETP (μg/mL)

48

2.54 ± 0.60

46

1.98 ± 0.73

−22.9 ± 19.5

< 0.01